Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 13-14/2018

18.09.2017 | review

Symptomatic treatment of dyspnea in advanced cancer patients

A narrative review of the current literature

verfasst von: Matthäus Strieder, Martin Pecherstorfer, Gudrun Kreye

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Dyspnea is a common, very distressing symptom in advanced cancer patients that challenges them, their relatives, and healthcare professionals. This narrative review summarizes important literature dealing with the evidence for opioids, benzodiazepines, oxygen, and steroids for treating dyspnea in advanced cancer patients.

Methods

A selective literature search was undertaken in PubMed, Embase, and the Cochrane Library and extended with literature from the reference lists of included studies up to April 2016. Inclusion criteria were that patients were suffering from advanced cancer and were receiving either opioids, benzodiazepines, corticosteroids, or oxygen. The outcome of interest was the reduction of dyspnea measured via a visual analogue scale (VAS), a numerical rating scale (NRS), or a Borg scale. This narrative review describes in detail the findings of 13 studies.

Results

Nine studies deal with the effectiveness of opioids for reducing dyspnea in advanced cancer patients. Five of these found a significant benefit to the use of opioids compared to a placebo. Three found no significant improvements, and two favored combinations of opioids and benzodiazepines. Few high-quality studies were available that used benzodiazepines (n = 3, no difference, significant improvement with midazolam + morphine, significant difference for midazolam) or oxygen (n = 2, both without significant difference). Only one study examined treating dyspnea with steroids in patients with advanced cancer, and that study indicated a benefit of steroids compared to a placebo.

Conclusions

Opioids are the drug of choice for treating refractory dyspnea in advanced cancer patients. Neither benzodiazepines nor oxygen showed significant benefit. In addition, there is insufficient literature available to draw a conclusion about the effectiveness of steroids for treating persistent dyspnea in advanced cancer patients.
Literatur
1.
Zurück zum Zitat Dyspnea ATSCo. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159(1):321–40. CrossRef Dyspnea ATSCo. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159(1):321–40. CrossRef
2.
Zurück zum Zitat Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung L‑, version 1.0, AWMF-Registernummer: 128/001OL. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung L‑, version 1.0, AWMF-Registernummer: 128/001OL.
3.
Zurück zum Zitat Pohl G, Gaertner J. Pathophysiology and diagnosis of dyspnea in patients with advanced cancer. Wien Med Wochenschr. 2009;159(23–24):571–6. CrossRef Pohl G, Gaertner J. Pathophysiology and diagnosis of dyspnea in patients with advanced cancer. Wien Med Wochenschr. 2009;159(23–24):571–6. CrossRef
4.
Zurück zum Zitat Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–52. CrossRef Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–52. CrossRef
5.
Zurück zum Zitat Bausewein C, Simon ST. Shortness of breath and cough in patients in palliative care. Dtsch Arztebl Int. 2013;110(33–34):563–71. quiz 72. PubMedPubMedCentral Bausewein C, Simon ST. Shortness of breath and cough in patients in palliative care. Dtsch Arztebl Int. 2013;110(33–34):563–71. quiz 72. PubMedPubMedCentral
6.
Zurück zum Zitat Guirimand F, Sahut d’izarn M, Laporte L, Francillard M, Richard JF, Aegerter P. Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer. Cancer Med. 2015;4(4):532–9. CrossRef Guirimand F, Sahut d’izarn M, Laporte L, Francillard M, Richard JF, Aegerter P. Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer. Cancer Med. 2015;4(4):532–9. CrossRef
7.
Zurück zum Zitat Weingartner V, Bausewein C, Higginson IJ, Scheve C, Murtagh FE, Voltz R, et al. Characterizing episodic breathlessness in patients with advanced disease. J Palliat Med. 2013;16(10):1275–9. CrossRef Weingartner V, Bausewein C, Higginson IJ, Scheve C, Murtagh FE, Voltz R, et al. Characterizing episodic breathlessness in patients with advanced disease. J Palliat Med. 2013;16(10):1275–9. CrossRef
9.
Zurück zum Zitat Currow DC, Smith J, Davidson PM, Newton PJ, Agar MR, Abernethy AP. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage. 2010;39(4):680–90. CrossRef Currow DC, Smith J, Davidson PM, Newton PJ, Agar MR, Abernethy AP. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage. 2010;39(4):680–90. CrossRef
10.
Zurück zum Zitat Mercadante S, Aielli F, Adile C, Valle A, Fusco F, Ferrera P, et al. Epidemiology and characteristics of episodic breathlessness in advanced cancer patients: an observational study. J Pain Symptom Manage. 2015;51:17–24. CrossRef Mercadante S, Aielli F, Adile C, Valle A, Fusco F, Ferrera P, et al. Epidemiology and characteristics of episodic breathlessness in advanced cancer patients: an observational study. J Pain Symptom Manage. 2015;51:17–24. CrossRef
11.
Zurück zum Zitat Kloke M, Cherny N, Committee EG. Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelinesdagger. Ann Oncol. 2015;26(Suppl 5):v169–v73. CrossRef Kloke M, Cherny N, Committee EG. Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelinesdagger. Ann Oncol. 2015;26(Suppl 5):v169–v73. CrossRef
12.
Zurück zum Zitat Ost DE, Ernst A, Grosu HB, Lei X, Diaz-Mendoza J, Slade M, et al. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. Chest. 2015;147(5):1282–98. CrossRef Ost DE, Ernst A, Grosu HB, Lei X, Diaz-Mendoza J, Slade M, et al. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. Chest. 2015;147(5):1282–98. CrossRef
15.
Zurück zum Zitat Simon ST, Koskeroglu P, Bausewein C. Pharmacological therapy of refractory dyspnoea : a systematic literature review. Schmerz. 2012;26(5):515–22. CrossRef Simon ST, Koskeroglu P, Bausewein C. Pharmacological therapy of refractory dyspnoea : a systematic literature review. Schmerz. 2012;26(5):515–22. CrossRef
16.
Zurück zum Zitat Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, et al. Dexamethasone for dyspnea in cancer patients: a pilot double-blind, randomized, controlled trial. J Pain Symptom Manage. 2016;52(1):8–16.e1. CrossRef Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, et al. Dexamethasone for dyspnea in cancer patients: a pilot double-blind, randomized, controlled trial. J Pain Symptom Manage. 2016;52(1):8–16.e1. CrossRef
17.
Zurück zum Zitat Allard P, Lamontagne C, Bernard P, Tremblay C. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage. 1999;17(4):256–65. CrossRef Allard P, Lamontagne C, Bernard P, Tremblay C. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage. 1999;17(4):256–65. CrossRef
18.
Zurück zum Zitat Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2001;57(11):939–44. CrossRef Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2001;57(11):939–44. CrossRef
19.
Zurück zum Zitat Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med. 1993;119(9):906–7. CrossRef Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med. 1993;119(9):906–7. CrossRef
20.
Zurück zum Zitat Davis CPK, A’Hern R, et al. Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliat Med. 1996;10:64–5. Davis CPK, A’Hern R, et al. Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliat Med. 1996;10:64–5.
21.
Zurück zum Zitat Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–8. CrossRef Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–8. CrossRef
22.
Zurück zum Zitat Bruera E, Sala R, Spruyt O, Palmer JL, Zhang T, Willey J. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005;29(6):613–8. CrossRef Bruera E, Sala R, Spruyt O, Palmer JL, Zhang T, Willey J. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005;29(6):613–8. CrossRef
23.
Zurück zum Zitat Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage. 2008;36(1):29–38. CrossRef Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage. 2008;36(1):29–38. CrossRef
24.
Zurück zum Zitat Hui D, Xu A, Frisbee-Hume S, Chisholm G, Morgado M, Reddy S, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manage. 2014;47(2):209–17. CrossRef Hui D, Xu A, Frisbee-Hume S, Chisholm G, Morgado M, Reddy S, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manage. 2014;47(2):209–17. CrossRef
26.
Zurück zum Zitat Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939–44. CrossRef Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939–44. CrossRef
27.
Zurück zum Zitat Harrison, TJR. A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer [dissertation]. Bristol: Bristol University, 2004. Harrison, TJR. A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer [dissertation]. Bristol: Bristol University, 2004.
28.
Zurück zum Zitat Navigante AH, Cerchietti LC, Castro MA, Lutteral MA, Cabalar ME. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage. 2006;31(1):38–47. CrossRef Navigante AH, Cerchietti LC, Castro MA, Lutteral MA, Cabalar ME. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage. 2006;31(1):38–47. CrossRef
29.
Zurück zum Zitat Navigante. Morphine versus midazolam as upfront therapy to relief dyspnea in ambulatory cancer patients while its underlying cause is sought or treated. (unpublished). Navigante. Morphine versus midazolam as upfront therapy to relief dyspnea in ambulatory cancer patients while its underlying cause is sought or treated. (unpublished).
30.
Zurück zum Zitat Navigante AH, Castro MA, Cerchietti LC. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage. 2010;39(5):820–30. CrossRef Navigante AH, Castro MA, Cerchietti LC. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage. 2010;39(5):820–30. CrossRef
31.
Zurück zum Zitat Uronis HE, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. Br J Cancer. 2008;98(2):294–9. CrossRef Uronis HE, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. Br J Cancer. 2008;98(2):294–9. CrossRef
32.
Zurück zum Zitat Ahmedzai SH, Laude E, Robertson A, Troy G, Vora V. A double-blind, randomised, controlled phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer. 2004;90(2):366–71. CrossRef Ahmedzai SH, Laude E, Robertson A, Troy G, Vora V. A double-blind, randomised, controlled phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer. 2004;90(2):366–71. CrossRef
33.
Zurück zum Zitat Booth S, Kelly MJ, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med. 1996;153(5):1515–8. CrossRef Booth S, Kelly MJ, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med. 1996;153(5):1515–8. CrossRef
34.
Zurück zum Zitat Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet. 1993;342(8862):13–4. CrossRef Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet. 1993;342(8862):13–4. CrossRef
35.
Zurück zum Zitat Bruera E, Sweeney C, Willey J, Palmer JL, Strasser F, Morice RC, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med. 2003;17(8):659–63. PubMed Bruera E, Sweeney C, Willey J, Palmer JL, Strasser F, Morice RC, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med. 2003;17(8):659–63. PubMed
36.
Zurück zum Zitat Philip J, Gold M, Milner A, Di Iulio J, Miller B, Spruyt O. A randomized, double-blind, crossover trial of the effect of oxygen on dyspnea in patients with advanced cancer. J Pain Symptom Manage. 2006;32(6):541–50. CrossRef Philip J, Gold M, Milner A, Di Iulio J, Miller B, Spruyt O. A randomized, double-blind, crossover trial of the effect of oxygen on dyspnea in patients with advanced cancer. J Pain Symptom Manage. 2006;32(6):541–50. CrossRef
37.
Zurück zum Zitat Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE 2nd, Marcello J, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010;376(9743):784–93. CrossRef Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE 2nd, Marcello J, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010;376(9743):784–93. CrossRef
38.
Zurück zum Zitat Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076–82. CrossRef Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076–82. CrossRef
39.
Zurück zum Zitat Blinderman CDB, Billings JA. Comfort care for patients dying in the hospital. N Engl J Med. 2016;374(17):1692–3. CrossRef Blinderman CDB, Billings JA. Comfort care for patients dying in the hospital. N Engl J Med. 2016;374(17):1692–3. CrossRef
Metadaten
Titel
Symptomatic treatment of dyspnea in advanced cancer patients
A narrative review of the current literature
verfasst von
Matthäus Strieder
Martin Pecherstorfer
Gudrun Kreye
Publikationsdatum
18.09.2017
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 13-14/2018
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-017-0600-4